Results 71 to 80 of about 75,353,973 (171)

Dissecting the angiogenic mechanism of pachychoroid polypoidal choroidal vasculopathy

iMeta, Volume 5, Issue 5, October 2026.
A prognosis‐oriented classification system was established to distinguish Pachy PCV from Non‐pachy PCV using a large multicenter dataset. Comparative plasma multi‐omics profiling of Pachy PCV, Non‐pachy PCV, and normal controls revealed unique upregulation of the fluid shear stress and atherosclerosis (FSS‐AS) and HIF‐1 signaling pathways in Pachy PCV.
Xinyu Zhao, Tiantian Cheng, Wenfei Zhang, Xingwang Gu, Qing Zhao, Yaning Chen, Lihui Meng, Jiaqi Zhang, Bintao Qiu, Lili Li, Shiyu Cheng, Zicheng Wang, Chuting Wang, Yuelin Wang, Zuyi Yang, Zhengming Shi, Ye Guo, Shengzhi Liu, Youxin Chen   +18 more
wiley   +1 more source

ECOG-ACRIN (E4805) Randomized Phase II Study to Determine the Effect of 2 Different Doses of Aflibercept in Patients with Metastatic Renal Cell Carcinoma [PDF]

, 2017
Background—Aflibercept is a recombinantly-produced fusion protein that has potent anti-VEGF activity. We tested whether aflibercept has clinical activity in clear cell renal cell carcinoma (ccRCC).
Shanks, James C., Dutcher, Janice, Liu, Glenn, Manola, Judith, Robert S. DiPaola, Groteluschen, David L., David L. Groteluschen, Pili, Roberto, Roberto Pili, Carducci, Michael A., James C. Shanks, Leonard L. Appleman, Opeyemi Jegede, Jegede, Opeyemi, Glenn Liu, Janice Dutcher, Michael A. Carducci, Appleman, Leonard L., Dakhil, Shaker R., DiPaola, Robert S., Judith Manola, Shaker R. Dakhil   +21 more
core   +1 more source

Early real-world anatomic response and interval extension after switching to aflibercept 8 mg in previously treated eyes with neovascular AMD or pachychoroid-related macular neovascularization

AJO International
Purpose: To evaluate early anatomic response and treatment-interval behavior after switching to aflibercept 8 mg in previously treated eyes with neovascular AMD or pachychoroid macular neovascularization under routine clinical practice.
Maria Emfietzoglou, Solomon Frances, Alexander Charonis   +2 more
doaj   +1 more source

Insights into the modulation of age‐related macular degeneration: Molecular and systems‐level perspectives

Acta Ophthalmologica, Volume 104, Issue S293, Page S4-S35, October 2026.
ENGLISH SUMMARY In developed countries, age‐related macular degeneration (AMD) is the leading cause of visual impairment in the aging population. Understanding of its pathogenesis is limited and the number of patients is predicted to continue rising. AMD is classified into two main forms: dry and neovascular AMD (dAMD and nAMD, respectively).
Hanna Heloterä
wiley   +1 more source

Inhibition of VEGF‐Induced Angiogenesis and Vascular Leakage by Bicistronic Co‐Expression of Aflibercept and COMP‐Ang1

Advanced Healthcare Materials, Volume 15, Issue 35, 18 September 2026.
A bicistronic rAAV8 vector encoding Aflibercept (Afb) and COMP‐cAng1 simultaneously coordinates VEGF clearance and Tie2‐mediated vessel maturation. In a 3D angiogenesis‐on‐a‐chip model, rAAV8‐Afb/cAng1 effectively reverses pathological barrier breakdown under clinical disease‐mimicking challenges.
Bong‐Kyu Kim, Jaehong Min, Sang‐Hee Park, Subeen Shin, Sangbin Yu, Jeong‐Eun Park, Sujin Kim, Wooju Park, Jihoon Ko, Sunjong Kwon   +9 more
wiley   +1 more source

Current Landscape and Future Perspectives of Diabetic Retinopathy Therapy: Pharmacological Targets, Precision Laser Technology, and Clinical Evidence

MedComm, Volume 7, Issue 7, July 2026.
Targeted biological agents targeting VEGF, integrin, dopamine D2 receptor, ROCK, and BCL‐XL have entered the clinical trial phase and deserve particular attention. The treatment paradigm has shifted toward personalized and precision medicine, positioning optimized SML as a promising adjunctive therapy.
Xinying Hu, Zhe Cha, Ao Lu, Wuping Xu, Xiaoqing Zhang, Sheng Miao, Haiwei Xu, Xuedong Xu   +7 more
wiley   +1 more source

Place of New Anti-Vascular Endothelial Growth Factor Agents in Recalcitrant Radiation Maculopathy: Case Reports

Case Reports in Ophthalmology
Introduction: Anti-vascular endothelial growth factor (VEGF) therapy is the main treatment alternative in radiation maculopathy as it reduces the macular edema and thereby improves the vision to some extent.
Özlem Ural Fatihoglu, Murat Tunc, Ali Osman Saatci   +2 more
doaj   +1 more source

Aflibercept high-dose (8mg) related intraocular inflammation (IOI) – a case series

BMC Ophthalmology
Background Monitoring for potential inflammatory events following intravitreal anti-vascular endothelial factor (VEGF) injection is crucial with the use of new agents such as aflibercept 8 mg.
Laura Hoffmann, Stephan Michels, Chiara Eandi, Muntadher Al Karam, Eva C. de Oliveira Figueiredo, Katja Hatz   +5 more
doaj   +1 more source

A phase I study of subcutaneously administered aflibercept (VEGF trap) in a new formulation in patients with advanced solid tumors [PDF]

, 2011
Targeting angiogenesis is a valid anti-cancer strategy. Aflibercept is designed to sequester circulating vascular endothelial growth factor (VEGF) by preventing VEGF from binding to its receptors.
Buzenet, Giliane, Giliane Buzenet, Jakob Dupont, Tew, William P, Sternas, Lars, David R. Spriggs, Rothenberg, Mace L, Lars Sternas, Wang-Gillam, Andrea, Spriggs, David R, Cooper, Wendy, Dupont, Jakob, Andrea Wang-Gillam, Sosman, Jeffrey A, Mace L. Rothenberg, Jeffrey A. Sosman, William P. Tew, Albert Craig Lockhart, Wendy Cooper, Lockhart, Albert Craig   +19 more
core   +1 more source

Intravitreal aflibercept 8 mg in patients from Japan with diabetic macular edema : 48-week subgroup analysis of the PHOTON trial [PDF]

In the pivotal PHOTON trial of patients with diabetic macular edema (DME), aflibercept 8 mg administered every 12 (8q12) and 16 (8q16) weeks demonstrated similar visual and anatomic outcomes with no new safety signals to aflibercept 2 mg every 8 weeks ...
Yoshida Shigeo, Chu Karen W, Berliner Alyson J, Voronca Delia, Kishino Genichiro, Tóth-Molnár Edit, Schmidt-Ott Ursula, Murata Toshinori, Shimura Masahiko, Kollaborációs szervezet PHOTON Investigators, Leal Sergio, Morgan-Warren Peter, Vitti Robert, Bhore Rafia, Sakamoto Taiji, Reed Kimberly, Suzuma Kiyoshi, Cheng Yenchieh, Schulze Andrea, Kobayashi Masato, et al., Yoshida, Shigeo, Berliner, Alyson J., Vitti, Robert, Suzuma, Kiyoshi, Cheng, Yenchieh, Leal, Sergio, Schmidt-Ott, Ursula, Voronca, Delia, Sakamoto, Taiji, Morgan-Warren, Peter, Shimura, Masahiko, Kishino, Genichiro, Schulze, Andrea, Reed, Kimberly, Kobayashi, Masato, Bhore, Rafia, Chu, Karen W., Murata, Toshinori   +38 more
core   +1 more source